Clinical characteristics and quality‐of‐life in patients surviving a decade of prostate cancer with bone metastases

Objective To describe characteristics and quality‐of‐life (QoL), and to define factors associated with long‐term survival in a subgroup of patients with prostate cancer with M1b disease. Patients and Methods The study was based on 915 patients from a prospective randomised multicentre trial (No. 5) by the Scandinavian Prostate Cancer Group, comparing parenteral oestrogen with total androgen blockade. Long‐term survival was defined as patients having an overall survival of ≥10 years, and logistic regression models were constructed to identity clinical predictors of survival. QoL during follow‐up was assessed using the European Organisation for Research and Treatment of Cancer Quality‐of‐Life Questionnaire – C30 version 1 (EORTC‐C30) ratings. Results In all, 40 (4.4%) of the 915 men survived for >10 years. Factors significantly associated with increased likelihood of surviving for >10 years in the univariate analyses were: absence of cancer‐related pain; Eastern Cooperative Oncology Group (ECOG) performance status of